Neurologist & Epileptologist

Dr. Sommerville is a board-certified neurologist and was in private practice in Lebanon, Pennsylvania 1980-1991. He was in charge of the EEG lab and was a consultant to a local psychiatric hospital and held a clinical position at the Hersey Medical Center. He joined the pharmaceutical industry in 1991 and since that time has been in Clinical Research for drugs in epilepsy, pain (abuse-deterrent opioids), and movement disorders including Parkinson Disease and Restless Leg Syndrome. He also contributed to research on a drug for prostatic hypertrophy. He has been the Medical Director or Vice-President for over one dozen NDA filings that have achieved approval. He has also been in charge of the clinical data for several drugs for epilepsy including vigabatrin, tiagabine, divalproex, intravenous valproate, lacosamide, diazepam injection, and most recently cannabidiol which received approval after a rapid clinical program of just four years. He has been in charge of clinical data for successful submissions in Parkinson Disease (rotigotine patch) and abuse-deterrent opioids (morphine and oxycodone formulations). He worked for a number of companies including Abbott, Schwarz, UCB, Marion Merrill Dow, King, Pfizer, and lastly Greenwich Biosciences (GW Pharma). He retired in 2018 after the submission of cannabidiol for Lennox-Gastaut and Dravet Syndrome. He has extensive experience in epilepsy and development of other CNS drugs.

Our team has the experience to develop pharmaceutical pain products